login
login

Europe Daily Bulletin No. 12142

22 November 2018
Contents Publication in full By article 30 / 37
COURT OF JUSTICE OF THE EU / Health
Reimbursement of a medicinal product for a use not covered by its marketing authorisation is not contrary to EU law, according to Court
Brussels, 21/11/2018 (Agence Europe)

The reimbursement by a national healthcare insurance system of a medicinal product for a use not covered by its marketing authorisation (off-label use) is not contrary to European Union law, the EU Court of Justice ruled on Wednesday 21 November (Case C-29/17). 

Roche Italia has been granted a marketing authorisation for Avastin, a drug to treat certain cancers. This drug is also frequently prescribed for the treatment of the eye disease, age-related macular degeneration ARMD, despite the...

Contents

ECONOMY - FINANCE - BUSINESS
SECTORAL POLICIES
INSTITUTIONAL
EXTERNAL ACTION
SOCIAL - CULTURE
COURT OF JUSTICE OF THE EU
NEWS BRIEFS